🇺🇸 FDA
Pipeline program

METFORMIN , Placebo 515

APHP230872

Phase 2 small_molecule active

Quick answer

METFORMIN , Placebo 515 for Portal hypertension (PHT) and consequences in complications of cirrhosis is a Phase 2 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Pari Pharma GmbH
Indication
Portal hypertension (PHT) and consequences in complications of cirrhosis
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials